Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Perspective Therapeutics, Inc.

NYSE: CATX · Life Sciences · 14 alerts · CIK 728387

Perspective Therapeutics, Inc. stories on ALFA USA NewsRead the news →
Share price
$0.9238Close, Nov 16
Market cap
$112M
Shares outstanding
120.76MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Perspective Therapeutics, Inc. filings on SEC EDGAR ↗

8:30 AM ET Form 4
Insider Buying

Perspective Therapeutics Director Frank Morich Buys $14K of Stock

Frank Morich, Director, bought 15,000 shares of Perspective Therapeutics, Inc. at $0.9364 a share, worth $14K in total on Nov 16, 2026. Shares held after the trade: 30,000 (+100.0%).

Value
$14K
Shares
15,000
Price
$0.9364
Role
Director
Holding change
+100.0%
Trade date
Nov 16, 2026
8:30 AM ET Form 4
Insider Buying

Perspective Therapeutics Director Robert F. Williamson III Buys $15.6K of Stock

Robert F. Williamson III, Director, bought 18,609 shares of Perspective Therapeutics, Inc. at $0.84 a share, worth $15.6K in total on Nov 12, 2026. Shares held after the trade: 28,473 (+188.7%).

Value
$15.6K
Shares
18,609
Price
$0.8400
Role
Director
Holding change
+188.7%
Trade date
Nov 12, 2026
8:30 AM ET Form 4
Insider Buying

Perspective Therapeutics Director Frank Morich Buys $15K of Stock

Frank Morich, Director, bought 15,000 shares of Perspective Therapeutics, Inc. at $0.9971 a share, worth $15K in total on Nov 12, 2026. Shares held after the trade: 15,000.

Value
$15K
Shares
15,000
Price
$0.9971
Role
Director
Trade date
Nov 12, 2026
8:30 AM ET Form 4
Insider Buying

Perspective Therapeutics Director Lori A. Woods Buys $20K of Stock

Lori A. Woods, Director, bought 23,750 shares of Perspective Therapeutics, Inc. at $0.8438 a share, worth $20K in total on Nov 12, 2026. Shares held after the trade: 28,557 (+494.1%).

Value
$20K
Shares
23,750
Price
$0.8438
Role
Director
Holding change
+494.1%
Trade date
Nov 12, 2026
8:30 AM ET Form 4
Insider Buying

Perspective Therapeutics CMO Markus Puhlmann Buys $29.6K of Stock

Markus Puhlmann, CMO, bought 35,000 shares of Perspective Therapeutics, Inc. at $0.8447 a share, worth $29.6K in total on Nov 12, 2026. Shares held after the trade: 178,542 (+24.4%).

Value
$29.6K
Shares
35,000
Price
$0.8447
Role
CMO
Holding change
+24.4%
Trade date
Nov 12, 2026
8:30 AM ET Form 4
Insider Buying

Perspective Therapeutics CEO Johan M. Spoor Buys $37.9K of Stock

Johan M. Spoor, CEO, bought 47,000 shares of Perspective Therapeutics, Inc. at $0.8073 a share, worth $37.9K in total on Nov 11, 2026. Shares held after the trade: 106,383 (+79.1%).

Value
$37.9K
Shares
47,000
Price
$0.8073
Role
CEO
Holding change
+79.1%
Trade date
Nov 11, 2026
4:36 PM ET 10-Q
Financial Results

Perspective Therapeutics Q3 2026 Results: Net Loss of $32.4M, Loss Widens

Perspective Therapeutics reported a net loss of $85.4 million for the nine months ended September 30, 2026, compared to $65.6 million in the prior year period, primarily driven by increased research and development expenses. The company significantly strengthened its balance sheet through a 2026 registered offering, ending the period with $201.7 million in cash, cash equivalents, and short-term investments.

Key figure
Net loss $32.4M
4:34 PM ET 8-K
Financial Results

Perspective Therapeutics Financial Results

Perspective Therapeutics reported financial results for the third quarter ended September 30, 2026, highlighting a cash position of $202 million which is expected to fund operations into 2028. The company reported a net loss of $24.7 million for the quarter and provided clinical updates on its lead radiopharmaceutical programs, including bamzireotide navoxetan and lapemelanotide zapixetar.

Term
Q3 2026

“We have presented clinical data that demonstrated the potential of delivering alpha radiation via our proprietary targeted oncology platform. With encouraging clinical findings observed to date that further support the best‑in‑class potential of bamzireotide, continued progress across two additional programs targeting melanoma and FAP-α-positive solid tumors, and investments in our manufacturing capabilities, we are well-positioned to lead the development of the field.”

Thijs Spoor, Perspective’s Chief Executive Officer
12:05 PM ET 8-K
Clinical Trial Data

Perspective Therapeutics Clinical Trial Data

Perspective Therapeutics announced updated interim results from its Phase 1/2a clinical trial of [212Pb]lapemelanotide zapixetar (VMT01) for advanced melanoma at the SITC 2026 meeting. The data showed a 75% disease control rate at the 3.0 mCi dose level with no dose-limiting toxicities or treatment-related serious adverse events reported across 20 patients. The findings support further investigation of this targeted alpha therapy for heavily pretreated patients who have failed prior immunotherapies.

7:01 AM ET 8-K
Clinical Trial Data

Perspective Therapeutics Clinical Trial Data

Perspective Therapeutics announced incremental Phase 1/2a clinical trial data for [212Pb]VMT-α-NET in patients with advanced neuroendocrine tumors (NETs). The data, presented at the NANETS 2026 Symposium, showed a 75% progression-free survival rate at 18 months and a 47% response rate in Cohort 3, supporting plans for a Phase 3 study initiation in 2027.

10:54 AM ET 8-K
Clinical Trial Data

Perspective Therapeutics Clinical Trial Data

Perspective Therapeutics announced updated interim Phase 1/2a results for [212Pb]VMT-α-NET in patients with SSTR2-expressing neuroendocrine tumors, showing objective response rates of 33% and 50% in Cohorts 2 and 3, respectively. The data demonstrated a 72% progression-free survival rate at 18 months with no dose-limiting toxicities, supporting the company's plan to initiate Phase 3 trials in 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.